Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

COMPLETED

Identifier: CI-TRIAL-00050763
Entity page: /trial/NCT01088048 ↗
Edges: 12

Neighbours: 3 cancers9 drugs
Drawn: 12 of 12 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia condition of …CONDITION_OFderived3 of 3
← condition of	Chronic Lymphocytic Leukemia registry condition “Chronic Lymphocytic Leukemia” mapped ONTOLOGY_EXACT	—	—	Chronic Lymphocytic Leukemia	1	Observed	clinicaltrials	graph →
← condition of	Indolent Non-Hodgkin Lymphoma

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia intervention of …INTERVENTION_OFderived9 of 9
← intervention of	Bendamustinesmall molecule registry intervention “Bendamustine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Bortezomibsmall molecule registry intervention “Bortezomib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Chlorambucilsmall molecule registry intervention “Chlorambucil” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Everolimussmall molecule registry intervention “Everolimus” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Fludarabinesmall molecule registry intervention “Fludarabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Idelalisibsmall molecule registry intervention “Idelalisib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Lenalidomidesmall molecule registry intervention “Lenalidomide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ofatumumabmonoclonal antibody registry intervention “Ofatumumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Rituximabmonoclonal antibody registry intervention “Rituximab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia intervention of …INTERVENTION_OFderived9 of 9

← intervention of

Bendamustinesmall molecule

registry intervention “Bendamustine” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Bortezomibsmall molecule

registry intervention “Bortezomib” (DRUG) mapped ALIAS

—